Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
A multicenter, randomized, prospective DKCRUSH-III study
BIFURCATION LESIONS Dr. Tahsin.N
PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.
Yangsoo Jang, M.D. Ph. D On behalf of CTO-IVUS investigator Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine,
Final Three-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer The.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park, MD, PhD, University.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Samsung Medical Center Cardiac & Vascular Center Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim,
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
(DES)+BVS +DCB for long diffuse LAD disease
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
American College of Cardiology Presented by Dr. Stephan Windecker
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Efficacy of Xience/Promus versus Cypher to rEduce Late Loss in stENT
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea Embargoed Until 10:45 a.m. ET, Tuesday, Nov. 10, 2015

Clinical usefulness of IVUS Improved clinical outcomes IVUS usage during PCI −There are no adequately powered randomized clinical trials to prove the clinical usefulness of IVUS for second-generation DESs. Background −The clinical outcomes of IVUS-guided second- generation DES implantation would be superior to those of angiography-guided DES implantation in a subset of patients with long coronary lesions. Hypothesis Hypothesis

Study Design A prospective, randomized, multi-center trial At 20 centers in Korea Enrollment period: Oct 2010 and July 2014 Key inclusion criteria Age 20 years or older Patients with typical chest pain or evidence of myocardial ischemia Non-emergent conditions Stent length ≥ 28 mm based on angiographic estimation Significant coronary artery stenosis (>50% based on visual estimate) considered for coronary revascularization with stent implantation Key exclusion criteria Acute ST-segment elevation or MI within 48 hours Age >80 years Cardiogenic shock Left ventricular ejection fraction <40% Left main disease requiring PCI Bifurcation lesion with 2-stent technique Chronic total occlusion Presence of previously implanted DES within 6 months In-stent restenosis lesion

DES implantation with IVUS guidance n = 700 DES implantation with angiography guidance n = 700 Patients with long coronary lesions (Implanted stent ≥28 mm in length) N = 1400 Study Design Clinical follow-up at 12 months Primary end point: MACE Cardiac death, target-lesion related MI, and ischemia-driven TLR Clinicaltrial.gov Identifier: NCT Trial Registration: clinicaltrial.gov Identifier: NCT

Statistical Analysis Sample size calculation  Assumption the overall incidence of MACE to be 7% at the 1-year in the angiography-guidance arm.  Superiority comparison with an expected risk reduction of 50% in the IVUS-guidance arm (α=0.05, β=0.8, drop-out=5- 10%)  Each 700 patients in the IVUS guidance arm and in the angiography guidance arm. Primary analysis  Intention-to-treat analysis with cumulative incidences of MACE at 1 year using the Kaplan-Meier estimates.  Comparison using the log-rank test. Turco MA, et al. JACC Cardiovasc Interv. 2008;1: Kim YH, et al. Circulation. 2006;114:

Procedure Criteria for stent optimization IVUS-guidance arm ‒ Minimal lumen CSA > lumen CSA at distal reference segments Angiography-guidance arm ‒ Angiographic residual diameter stenosis <30% and the absence of angiographically detected dissection

Study Flow Underwent angiography-guidance PCI as randomized Underwent IVUS-guidance PCI Withdrew consent Lost to follow-up Underwent IVUS-guidance PCI as randomized Underwent angiography-guidance PCI Withdrew consent Lost to follow-up 700Included in primary analysis700Included in primary analysis 700Randomized to undergo IVUS-guidance PCI 700 Randomized to undergo angiography-guidance PCI Excluded 13372Patients underwent coronary angiography during the study inclusion period 1400 Randomized 22 8 Physician preference in complex lesions Angiographically ambiguous anatomy 5 17 Technical failure to deliver IVUS catheter Physician decision due to unfavorable coronary anatomy

Baseline Characteristics CharacteristicsIVUS-guidanceAngiography-guidanceP value No. of patients700 Age, y64 (9).54 Male sex483 (69)481 (69).91 Hypertension454 (65)444 (63).58 Diabetes mellitus250 (36)256 (37).74 Left ventricular ejection fraction, %62.9 ± ± Clinical presentation.36 Stable angina358 (51)356 (51) Unstable angina242 (35)226 (32) Acute myocardial infarction100 (14)118 (17) No. of treated lesions per patients1.34 (0.56)1.36 (0.57).57 Duration of DAPT, days 365 (180, 365).15 Coronary arteries.14 Left anterior descending artery 455 (65)419 (60) Left circumflex artery 96 (14)108 (15) Right coronary artery 149 (21)173 (25) Baseline QCA data Reference vessel diameter, mm 2.89 ± ± Minimum lumen diameter, mm 0.83 ± ± Diameter stenosis, % 71.1 ± ± Lesion length, mm 34.7 ± ± Stent length, mm39.3 ± ±

Angiographic and Procedural Characteristics CharacteristicsIVUS-guidance Angiography- guidance P value Adjunct post-dilatation534 (76)402 (57)<.001 Final balloon size, mm3.14 ± ± 0.42<.001 Overlapping stent145 (21)138 (20).64 No. of stents per lesions1.3 (0.5).48 Stent edge dissections15 (2)13 (2).70 Coronary perforation Maximal inflation pressure, atm16.5 ± ± Post-intervention QCA data Reference vessel diameter, mm3.03 ± ± Minimum lumen diameter, mm2.64 ± ± 0.39<.001 Diameter stenosis, %12.79 ± ±

Clinical outcomes at 1 year IVUS- guidance (n=700) Angiography- guidance (n=700) Hazard ratio (95% CI) Log- Rank P value Primary End Point MACE19 (2.9%)39 (5.8%)0.48 (0.28–0.83).007 Secondary End Point Cardiac death3 (0.4%)5 (0.7%)0.60 ( ).48 Target lesion related MI01 (0.1%)-.32 Ischemia-driven TLR17 (2.5%)33 (5.0%)0.51 ( ).02 Stent thrombosis2 (0.3%) 1.00 ( )1.00 Acute1 (0.1%) -- Sub-acute1 (0.1%)0-- Late01 (0.1%)--

Primary End Point Time Since Randomization, mo No. at risk Angiography arm IVUS arm Angiography-guidance IVUS-guidance HR, 0.48 (95% CI, ) Log-rank P = % 2.9% Patients with Primary End Point Event, %

Post-intervention IVUS analysis in subgroup of IVUS guidance Procedural and IVUS Characteristics Patients meeting the IVUS criteria Patients not meeting the IVUS criteria P value No. of patients Adjunct post-dilatation282 (78)237 (75).34 Final balloon size, mm3.15 ± 0.45)3.13 ± Maximal inflation pressure, atm16.5 ± ± Proximal reference EEM area, mm ± ± Proximal reference lumen area, mm ± ± Minimal lumen area, mm ± ± Distal reference EEM area, mm ± ± 3.83<.001 Distal reference lumen area, mm ± ± 1.68<.001

Time Since Randomization, mo No. at risk Not meeting the criteria Meeting the criteria HR, 0.31 (95% CI, ) Log-rank P = % 1.5% Patients with Primary End Point Event, % Patients meeting the IVUS-criteria for stent optimization Patients not meeting the IVUS-criteria for stent optimization Primary End Point

Conclusions Among patients requiring long coronary stent implantation, the use of IVUS-guidance for DES implantation was associated with a significant 2.9% absolute reduction and 48% relative reduction in the risk of MACE at 1 year, compared with angiography-guidance. Our findings suggest better clinical outcomes of MACE with IVUS-guidance compared to angiography-guidance for DES implantation, particularly for diffuse long lesions.

Dreams will come true